Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Efecto del polimorfismo +2138InsCAGACC en el gen del receptor 3 de la melanocort...
Información de la revista
Vol. 54. Núm. 5.
Páginas 249-254 (Mayo 2007)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 54. Núm. 5.
Páginas 249-254 (Mayo 2007)
Originales
Acceso a texto completo
Efecto del polimorfismo +2138InsCAGACC en el gen del receptor 3 de la melanocortina en el riesgo de obesidad en población española
Effect of the +2138InsCAGACC polymorphism in the melanocortin receptor 3 gene on obesity risk in the spanish population
Visitas
4253
Francesc Francésa,
Autor para correspondencia
ffrances@uv.es

Correspondencia: Dr. F. Francès Bozal. Departamento de Medicina Preventiva. Facultad de Medicina. Avda. Blasco Ibañez, 15. 46010 Valencia. España.
, José Vicente Sorlía,b, Marisa Guilléna, Olga Portolésc, Dolores Corellaa
a Unidad de Investigación en Epidemiología Genética y Molecular. Departamento de Medicina Preventiva y Salud Pública. Universitat de València. Valencia. España
b Centro de Salud de Atención Primaria de Xirivella. Valencia. España
c Departamento de Lenguajes y Sistemas Informáticos. Universitat Jaume I. Castellón de la Plana. España
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Objetivo

El receptor 3 de la melanocortina (MC3R) ha sido implicado en la regulación de la homeostasis energética y en el peso corporal. Nuestro objetivo es conocer si el polimorfismo +2138InsCAGACC en dicho gen se asocia con el riesgo de obesidad en población española.

Material y método

Se ha realizado un estudio de casos y controles con 303 casos de obesidad y 606 controles apareados por sexo y edad. Se determinaron variables antropométricas y del estilo de vida y el polimorfismo +2138InsCAGACC en el gen del MC3R.

Resultados

La frecuencia alélica para la variante +2138InsCAGACC para el total de la población fue de 0,29, y resultó ligeramente menos frecuente en el grupo de casos que en el de controles. Así, en el análisis bruto, los portadores de la variante +2138InsCAGACC presentan un menor riesgo de obesidad, en el límite de la significación estadística (odds ratio [OR]=0,73; intervalo de confianza [IC] del 95%, 0,53-1,01; p=0,056), que apenas se modificó al controlar por posibles variables de confusión. Al analizar la asociación entre este polimorfismo y el peso corporal, se encontró una asociación estadísticamente significativa con un menor peso. Esta asociación fue específica del grupo de personas obesas, de forma que los portadores de la variante +2138InsCAGACC presentaron un menor peso medio que los no portadores (99,8±22,7 frente a 94,2±20,7kg; p=0,04).

Conclusiones

El polimorfismo +2138InsCAGACC se asocia con menor peso corporal en personas obesas y tiende a asociarse a un menor riesgo de obesidad. Son necesarios más estudios en otras poblaciones para confirmar estos hallazgos.

Palabras clave:
Melanocortina
Receptor
Obesidad
Polimorfismo
Objective

The melanocortin 3 receptor gene (MC3R) has been implicated in the regulation of energy homeostasis and body weight. Our aim was to determine whether the +2138InsCAGACC polymorphism in that gene is associated with obesity risk in the Spanish population.

Material and method

A case-control study was carried out, including 303 obesity cases paired by sex and age with 606 controls. Anthropometrical data, lifestyle, and the +2138InsCAGACC polymorphism in the MC3R gene were determined.

Results

The allele frequency for the +2138InsCAGACC variant for the total population was 0.29 and was slightly less frequent in cases than in controls. Thus, in the raw analysis, +2138InsCAGACC carriers showed a lower obesity risk, at the limit of statistical significance (odds ratio [OR]=0.73; 95% confidente interval [CI], 0.53-1.01; p=0.056), which hardly changed after adjustment for potential confounders. Analysis of the association between this polymorphism and body weight revealed a statistically significant association with lower weight. This association was specific for the obese group; thus +2138InsCAGACC carriers had a lower mean weight than non-carriers (99.8±22.7 vs 94.2±20.7kg; p=0.04).

Conclusions

The +2138InsCAGACC polymorphism is associated with lower body weight in obese people and tends to be associated with a lower risk of obesity. Further studies are required to confirm these findings.

Key words:
Melanocortin
Receptor
Obesity
Polymorphism
El Texto completo está disponible en PDF
Bibliografía
[1.]
M. Neira, M. De Onis.
Preventing obesity: a public health priority in Spain.
[2.]
A.M. Spiegel, B.M. Alving.
Executive summary of the Strategic Plan for National Institutes of Health Obesity Research.
Am J Clin Nutr, 82 (2005), pp. S211-S214
[3.]
D.M. Muoio, C.B. Newgard.
Obesity-related derangements in metabolic regulation.
Annu Rev Biochem, 75 (2006), pp. 367-401
[4.]
A.M. Prentice.
Early influences on human energy regulation: thrifty genotypes and thrifty phenotypes.
Physiol Behav, 86 (2005), pp. 640-645
[5.]
H.N. Lyon, J.N. Hirschhorn.
Genetics of common forms of obesity: a brief overview.
Am J Clin Nutr, 82 (2005), pp. S215-S217
[6.]
A.A. Butler.
The melanocortin system and energy balance.
[7.]
J. Panskepp, P. Reilly, P. Bishop, R.B. Meeker, T.R. Vilberg, A.J. Kastin.
Effects of alpha-MSH on motivation, vigilance and brain respiration.
Pharmacol Biochem Behav, 5 (1976), pp. 59-64
[8.]
I. Gantz, H. Miwa, Y. Konda, Y. Shimoto, T. Tashiro, S.J. Watson, et al.
Molecular cloning, expression, and gene localization of a fourth melanocortin receptor.
J Biol Chem, 268 (1993), pp. 15174-15179
[9.]
I. Gantz, T. Tashiro, C. Bancroft, Y. Konda, Y. Shimoto, H. Miwa, et al.
Localization of the genes encoding the melanocortin-2 (adrenocorticotropic hormone) and melanocortin-3 receptors to chromosomes 18p11.2 and 20q13.2-q13.3 by fluorescence in situ hybridization.
Genomics, 18 (1993), pp. 166-167
[10.]
I. Gantz, Y. Konda, T. Tashiro, Y. Shimoto, H. Miwa, G. Munzert, et al.
Molecular cloning of a novel melanocortin receptor.
J Biol Chem, 268 (1993), pp. 8246-8250
[11.]
A.A. Butler, R.A. Kesterson, K. Khong, M.J. Cullen, M.A. Pelleymounter, J. Dekoning, et al.
A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse.
Endocrinology, 141 (2000), pp. 3518-3521
[12.]
A.A. Butler, R.D. Cone.
The melanocortin receptors: lessons from knockout models.
Neuropeptides, 36 (2002), pp. 77-84
[13.]
R. Branson, N. Potoczna, J.G. Kral, K.U. Lentes, M.R. Hoehe, F.F. Horber.
Binge eating as a major phenotype of melanocortin 4 receptor gene mutations.
N Engl J Med, 348 (2003), pp. 1096-1103
[14.]
D.L. Marks, V. Hruby, G. Brookhart, R.D. Cone.
The regulation of food intake by selective stimulation of the type 3 melanocortin receptor (MC3R).
[15.]
I.M. Heid, C. Vollmert, A. Hinney, A. Doring, F. Geller, H. Lowel, et al.
Association of the 103I MC4R allele with decreased body mass in 7937 participants of two population based surveys.
J Med Genet, 42 (2005), pp. e21
[16.]
J. Rutanen, J. Pihlajamaki, P. Karhapaa, I. Vauhkonen, J. Kuusisto, L. Moilanen Mykkanen, et al.
The Val103Ile polymorphism of melanocortin-4 receptor regulates energy expenditure and weight gain.
Obes Res, 12 (2004), pp. 1060-1066
[17.]
F. Geller, K. Reichwald, A. Dempfle, T. Illig, C. Vollmert, S. Herpertz, et al.
Melanocortin-4 receptor gene variant I103 is negatively associated with obesity.
Am J Hum Genet, 74 (2004), pp. 572-581
[18.]
R.E. Magenis, L. Smith, J.H. Nadeau, K.R. Johnson, K.G. Mountjoy, R.D. Cone.
Mapping of the ACTH, MSH, and neural (MC3 and MC4) melanocortin receptors in the mouse and human.
Mamm Genome, 5 (1994), pp. 503-508
[19.]
A.V. Lembertas, L. Perusse, Y.C. Chagnon, J.S. Fisler, C.H. Warden, D.A. Purcell-Huynh, et al.
Identification of an obesity quantitative trait locus on mouse chromosome 2 and evidence of linkage to body fat and insulin on the human homologous region 20q.
J Clin Invest, 100 (1997), pp. 1240-1247
[20.]
N. Boucher, C.M. Lanouette, M. Larose, L. Perusse, C. Bouchard, Y.C. Chagnon.
A +2138InsCAGACC polymorphism of the melanocortin receptor 3 gene is associated in human with fat level and partitioning in interaction with body corpulence.
Mol Med, 8 (2002), pp. 158-165
[21.]
World Health Association. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation on Obesity, Geneva, 3-5 June, 1997. Geneve, Switzerland: World Health Association, 1998 (WHO TRS 984).
[22.]
D. Corella, L. Qi, J.V. Sorli, D. Godoy, O. Portoles, O. Coltell, et al.
Obese subjects carrying the 11482G>A polymorphism at the perilipin locus are resistant to weight loss after dietary energy restriction.
J Clin Endocrinol Metab, 90 (2005), pp. 5121-5126
[23.]
D. Corella, M. Guillén, C. Saiz, O. Portoles, A. Sabater, J. Folch, et al.
Associations of LPL and APOC3 gene polymorphisms on plasma lipids in a Mediterranean population: interaction with tobacco smoking and the APOE locus.
J Lipid Res, 43 (2002), pp. 416-427
[24.]
N. Feng, S.F. Young, G. Aguilera, E. Puricelli, D.C. Adler-Wailes, N.G. Sebring, et al.
Co-occurrence of two partially inactivating polymorphisms of MC3R is associated with pediatric-onset obesity.
Diabetes, 54 (2005), pp. 2663-2667
[25.]
C. Schalin-Jantti, K. Valli-Jaakola, L. Oksansen, E. Martelin, K. Laitinen, T. Krusius.
Melanocortin-3-receptor gene variants in morbid obesity.
Int J Obes Relat Metab Disord, 27 (2003), pp. 70-74
[26.]
Y.S. Lee, L.K. Poh, K.Y. Loke.
A novel melanocortin 3 receptor gene (MC3R) mutation associated with severe obesity.
J Clin Endocrinol Metab, 87 (2002), pp. 1423-1426
[27.]
M. Rached, A. Buronfosse, M. Begeot, A. Penhoat.
Inactivation and intracellular retention of the human I183N mutated melanocortin 3 receptor associated with obesity.
Biochim Biophys Acta, 1689 (2004), pp. 229-234

Este trabajo ha sido parcialmente financiado por la Generalitat Valenciana (grupos 2004-43) y por el Instituto de Salud Carlos III (CIBER/06/03/0035).

Copyright © 2007. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos